Guideline for Managing Elevated AST in Patients Receiving Apixaban

Apixaban Management Based on AST Elevation Grade

Grade 1 elevation (1–3 × ULN) in asymptomatic patients: Continue apixaban with close monitoring of liver enzymes 1–2 times weekly while evaluating alternative causes. 1
Grade 2 elevation (3–5 × ULN): Temporarily hold apixaban, discontinue other hepatotoxic drugs, and monitor liver tests every 3 days; consider a short course of prednisone (0.5–1 mg/kg/day) if no improvement within 3–5 days, and may restart apixaban once AST falls to Grade 1 and prednisone ≤10 mg/day. 1
Grade 3–4 elevation (>5 × ULN): Permanently discontinue apixaban, initiate methylprednisolone 1–2 mg/kg (or equivalent), obtain hepatology consultation, and if steroids fail, proceed to liver biopsy to exclude other diagnoses. 1, 2

Trial exclusion criteria: Patients with transaminases >2 × ULN or total bilirubin >1.5 × ULN were excluded from apixaban trials; therefore, apixaban should not be started in moderate‑to‑severe hepatic impairment. 4
Metabolic pathway: Apixaban is primarily metabolized by hepatic CYP3A4; dose adjustments or avoidance are recommended in significant liver dysfunction. 4

Screening: All patients receiving immunosuppressive therapy or biologics should be screened for hepatitis B surface antigen (HBsAg) before initiating treatment. 5, 6
Definition & typical enzyme rise: Reactivation is defined as a ≥100‑fold increase in HBV DNA or reappearance of viremia; it typically produces AST/ALT rises of 5–10 × ULN within weeks. 5
Prophylaxis: In HBsAg‑positive individuals undergoing corticosteroid or tocilizumab therapy, prophylactic nucleoside‑analogue antiviral therapy should be started to prevent reactivation. 6

Incorrect attribution: Do not attribute isolated AST elevation to apixaban without first excluding other causes; continuation beyond the thresholds of AST > 3 × ULN with symptoms or > 5 × ULN without symptoms is contraindicated and requires immediate drug discontinuation. 1, 2
Missing hepatitis B screening: Failure to screen for hepatitis B reactivation in immunosuppressed patients can lead to acute liver failure; proactive screening and prophylaxis are essential. 5, 6